Gilead Offers Egypt New Hepatitis C Drug at 99 Percent Discount
March 25, 2014
This article was reported by Reuters.
Reuters reported that the pharmaceutical company Gilead Sciences has agreed to sell its new hepatitis C virus (HCV) drug Sovaldi to the Egyptian government for $300 for a one-month supply. The total cost for the recommended 12-week regimen would be $900, instead of the $84,000 price tag in the United States. Gilead agreed to the 99-percent discount because Egypt has the highest HCV prevalence in the world, due largely to the use of poorly sterilized needles during campaigns to eradicate the parasitic disease schistosomiasis. Gilead would offer the reduced price to government clinics; patients could access treatment programs after registering during the first half of 2014. The World Health Organization reported that most of the 150 million people with chronic HCV live in developing countries.View Full Article
Add Your Comment:
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)